- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Agfa brings TeraRecon’s 3D to IMPAX
The effects of an agreement signed in the run-up to RSNA 2010 changed the IT approaches of two companies on the exhibit floor, TeraRecon and Agfa HealthCare. One week before the imaging community trekked to Chicago, these two companies cut a deal to make TeraRecon’s thin-client iNtuition an integral part of Agfa’s IMPAX 6 PAC system
The effects of an agreement signed in the run-up to RSNA 2010 changed the IT approaches of two companies on the exhibit floor, TeraRecon and Agfa HealthCare. One week before the imaging community trekked to Chicago, these two companies cut a deal to make TeraRecon’s thin-client iNtuition an integral part of Agfa’s IMPAX 6 PAC system.
Both companies are touting the integrated product at their booths on the RSNA 2010 exhibit floor. Purchasers don’t have to buy TeraRecon’s thin-client system along with IMPAX 6, but with the increasing emphasis on 3D and other advanced visualization techniques, they may feel the need. The value-added reseller agreement with TeraRecon gives IMPAX purchasers a wide range of advanced visualization and decision-support tools for radiology, cardiology, and nuclear medicine applications.
Advanced 3D capabilities and automated tools for volume reconstruction and image analysis are a mouse click away as part of a scalable and flexible software license that can be deployed across multiple servers. This license extends to the zero-footprint AquariusWEB viewer, which provides remote access to images, as well as vascular analyses and other quantitative results.
And there is an added bonus in that AquariusWEB can connect the user to electronic medical records. The zero-footprint viewer provides an easy way to plug into EMR systems, since it can be launched from a URL referring to the iNtuition server and the patient or study.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
